- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01155505
Lenalidomide and Paclitaxel in Advanced Solid Tumors
Phase Ib of CC-5013 and Paclitaxel in Patients With Advanced Solid Tumors
This is a dose finding, open-label, uncontrolled, dose-escalation trial to determine the maximum Tolerated Dose (MTD) of the combination of CC-5013 (Lenalidomide)and paclitaxel in patients with advanced solid tumors.
Other purposes of the study are:
- Define the safety profile of the CC-5013 and paclitaxel given in combination
- Define the pharmacokinetics of CC-5013 and paclitaxel given in combination
- Define the pharmacodynamic effects of the combination by monitoring potential biomarkers of the different biological activities of each component of the regimen
- Define the optimal biological dose (OBD) and the dose recommended (RD) for phase II studies in selected tumor types (breast, ovary, prostate, NSCLC)
- Collect evidence of antitumor activity in selected tumor types
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The new immunomodulatory drugs (IMiD) derivatives of thalidomide (CC-5013 lenalidomide and CC4047 pomalidomide) are endowed of direct antitumor activity besides the indirect effects attributed to antiangiogenic, antiinflammatory and T-cell co-stimulatory properties.
Combination therapy with cytotoxic agents or other anticancer drugs could lead to additive or synergistic interactions and support their clinical development in tumor types in which the specific activities of IMiDs could be of potential value.
Combinations with weekly paclitaxel could be of interest because of its antiangiogenic activity, antitumor activity in prostate, NSCLC, ovary, breast cancer, tumor types in which IMiD could be of clinical value because of either enhancement of tumor specific immunity (ovary, prostate) or inhibition of Treg function (breast, NSCLC, ovary).
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Milan, Italy, 20133
- Fondazione IRCSS Istituto Nazionale dei Tumori
-
-
-
-
-
Bellinzona, Switzerland, 6500
- Istituto Oncologico della Svizzera Italiana
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histological/cytological diagnosis of solid tumors for which a treatment with paclitaxel could be indicated (preferentially ovary, breast, prostate, NSCLC)
- Documented progression of the tumor in the 3 months preceding the study
- Expected survival ≥ 3 months
- Age 18-75 years
- ECOG PS 0-1
measurable/evaluable disease during escalation phase, according to modified RECIST criteria. For patients with ovarian and prostatic cancer, tumor markers (CA125 for ovarian and PSA for prostatic) are accepted as only evidence. Measurable/evaluable disease is mandatory during the RD expansion phase
•≤ 2 prior lines of chemotherapy for metastatic disease. For ovarian patients reintroduction of a platinum at relapse, after an initial response lasting > 6 months is considered one chemotherapy regimen only
- Adequate contraception for all fertile patients
- Adequate hematological function as defined by: ANC ≥ 1.5 x 109/L, platelet count ≥100 x 109/L, hemoglobin ≥ 10 g/dL.
- Normal PTand INR; fibrinogen > lower Normal Limit (LNL)
- Adequate renal function, as defined by: creatinine ≤ 1.5 x UNL
Adequate hepatobiliary function, as defined by the following baseline liver function tests:
- total serum bilirubin within upper normal limit (UNL)
- alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤2.5xUNL or ≤ 5xUNL in case of liver metastases; alkaline phosphatase (AP) ≤ 2.5xUNL. If total alkaline phosphatase (AP) > 2.5xUNL, alkaline phosphatase liver fraction must be ≤ 2.5xUNL.
- albumin ≥ 2.5 g/dL
Exclusion Criteria:
- History of DVT or coagulation disturbances
- Need of treatment with oral anticoagulants or LMW heparin
- Clinical resistance to taxanes defined as progression during therapy or within 6 months from the end of adjuvant treatment
- Known or prior hypersensitivity to taxanes or drugs containing chemophor, or to thalidomide (or analogues)
- Preexisting peripheral neuropathy > grade 1
- Concomitant treatment with non steroid anti-inflammatory agents (NSAIA), high dose steroids or immunosuppressants
- Concomitant hormonal treatment (including those with antiandrogenic)
- Radiotherapy involving > 30% of the active bone marrow
- Radiotherapy ≤ 4 weeks prior to enrolment
- Other chemotherapy treatment ≤ 4 weeks prior to enrolment, at least 6 weeks for nitrosoureas or mitomycin C, or investigational drugs
- Symptomatic brain metastases
- Active infection
- Gastro-intestinal abnormalities, inability to take oral medication, any condition affecting absorption
- Impaired cardiac function including any of the following:
History of cardiac disease, such as myocardial infarction, in the year prior to enrollment in the clinical trial, symptomatic/uncontrolled angina pectoris, congestive heart failure or uncontrolled cardiac ischemia, or arrhythmia, abnormal left ventricular ejection fraction, or uncontrolled arterial hypertension.
- Major surgery in the two weeks prior to entering the clinical trial
- Concurrent treatment with any other anti-cancer therapy
- History of another neoplastic disease (except basal cell carcinoma of the skin or uterine cervix carcinoma in situ adequately treated), unless in remission for ≥ 5 years
- Patient unable to comply with the study protocol owing to psychological, social or geographical reasons
- Pregnant and lactating women
- Men and women of childbearing potential who are not using an effective method of contraception
- Participation in another clinical trial or treatment with any investigational product within 30 days prior to inclusion in this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CC-5013 in combination with Paclitaxel
Cohorts of 3 evaluable patients will initially be entered within each dose level, sequentially. In each dose level the second and third patient will enter 2 weeks after the first one. The second and third patient may be treated simultaneously, except if a DLT is reported in the first patient, in which case the second and third patient should be treated sequentially, at least one week apart. Dose escalation will be done when all the patients included in each DL will finish the first treatment cycle. Three additional patients will be sequentially entered (separated by one week each other) if one DLT is observed in cycle 1 among the first 3 patients entered within a dose level. If a DLT is observed in a second patient at this dose level, no further dose escalation will be allowed and the dose level will be considered the MTD. Once the RD (one level below the MTD) has been defined, additional patients (up to 12) will be treated in order to confirm the safety profile of the combination. |
CC-5013 given PO daily on D1-D14 every 21 days and Paclitaxel administered IV over 1 hour on d1 and 8 every 21 days until tumor progression or unacceptable toxicity
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Define the MTD of the combination of CC-5013 and paclitaxel in patients with advanced solid tumors
Time Frame: 4 weeks after the first drug administration
|
Number of Dose-Limiting Toxicities (DLTs)
|
4 weeks after the first drug administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety profile of the drug combination
Time Frame: from the first administration to 30 days after the trial end
|
Physical examination, laboratory and instrumental assessments and AE type and frequency
|
from the first administration to 30 days after the trial end
|
Pharmacokinetics of CC-5013 and paclitaxel given in combination
Time Frame: untill 4 weeks after the first drug administration
|
CC-5013 and paclitaxel plasma concentration
|
untill 4 weeks after the first drug administration
|
the pharmacodynamic effects of CC-5013 and paclitaxel given in combination
Time Frame: from the first drug administration to 30 days after trial end
|
Increase (%) in selected serum cytokines (IL2, IL6, IL10, IL12, TNFα, γIF and TGFβ). T-cell phenotyping:
|
from the first drug administration to 30 days after trial end
|
Evidence of antitumor activity in selected tumor types
Time Frame: From the first drug administration to 30 days after the trial end
|
Response Rate according to RECIST criteria
|
From the first drug administration to 30 days after the trial end
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Cristiana Sessa, MD, Istituto Oncologico della Svizzera Italiana -6500 Bellinzona, Switzerland
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- S095LEPT01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Vividion Therapeutics, Inc.RecruitingAdvanced Solid Tumors | Advanced Hematologic TumorsUnited States, Australia
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors, Neoplasms, Advanced SolidHungary
Clinical Trials on Lenalidomide (CC-5013)
-
Celgene CorporationCompletedMyelodysplastic SyndromesUnited States, Denmark, Australia, Belgium, Czech Republic, France, Germany, Greece, Italy, Netherlands, Russian Federation, Spain, Sweden, Switzerland, United Kingdom
-
CelgeneCompletedChronic Lymphocytic Leukemia | Leukemia, B-Cell, ChronicCanada, United States, Germany, Italy, Spain, Sweden, United Kingdom
-
Celgene CorporationTerminatedDiffuse Large B-cell LymphomaUnited States, Canada, Australia
-
CelgeneCompletedMyelodysplastic SyndromesUnited States, Germany
-
The Cleveland ClinicNational Cancer Institute (NCI)CompletedKidney CancerUnited States
-
CelgeneCompletedMultiple MyelomaUkraine, Russian Federation
-
King's College Hospital NHS TrustCompleted
-
M.D. Anderson Cancer CenterCelgene CorporationCompleted
-
Celgene CorporationCompletedRadiculopathyUnited States
-
National Cancer Institute (NCI)CompletedAdult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation... and other conditionsUnited States